HACKENSACK, N.J. -- Doctors at Hackensack University Medical Center continue to use a new endovascular thoracic stent graft after participating in clinical trials to help it gain FDA approval.
Hospital officials announced recently they successfully have used the emerging treatment device in patients with thoracic aneurysms.
Hackensack doctors worked with Cook Medical to conduct the clinical trials needed for FDA approval of what officials call the lowest-profile, minimally invasive endovascular stent graft.
In the first known case of its kind in the United States, Michael Wilderman, chief of endovascular surgery at the medical center, placed the device in a ruptured and dissecting thoracic aneurysm, hospital officials said.
Greg Simonian, executive vice chairman and chief of operations of the Heart and Vascular Hospital at the Hackensack center, used the first commercially available device during an elective thoracic aneurysm repair just a few weeks ago, hospital officials said.
“I am proud of our team for leading the way by safely and effectively providing groundbreaking technology in service of our patients,” said Martin S. Karpeh Jr., chairman of the department of surgery at the medical center.
Wilderman continues to perform successful endovascular thoracic aneurysm repairs using this new technology, hospital officials said.
“These successful outcomes might not have occurred with the prior generation of standard thoracic endografts,” Wilderman said.
Hospital officials said Hackensack's participation in the clinical trials helped them get early access to the device once it was approved by the FDA.
Hackensack University Medical Center is a 775- bed nonprofit teaching and research hospital in Bergen County. It is the largest provider of inpatient and outpatient services in the state, hospital officials said.
For details, visit the hospital's website .